NOW OF: A US single-arm, single-centre, ph 2 trial assesses the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma.
#gicsm
thelancet.com/journals/lanon…